A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Contact Person: Tanya Pozniansky
Please contact l: firstname.lastname@example.org Adjuvant B-55
Location: PAMF (Peninsula/South Bay)
View study details on ClinicalTrials.gov
Gillian L. Hsieh, M.D., Irene Wu, M.D., Edmund W. Tai, M.D., Janet Wang, M.D., Paula D. Kushlan, M.D., M. Dwight Chen, M.D., Glenn D. Wong, D.O., Natalia Colocci, M.D., Ph.D., Albert Pisani, M.D., Michael C. Wu, M.D., Kim-Son Nguyen, M.D., Huan T. Ha, M.D., Bryant C. Sheh, M.D., Priya Chakravarthi, M.D., Monique de Bruin, M.D., MPH, David S. Leibowitz, M.D., FACP, Derrick Wong, M.D.
February 01, 2019